Biovie Inc (BIVI)

Name: Biovie Inc (BIVI) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Biovie Inc (BIVI)

Stock Card

$2.17

$-0.03 (-1.14%)

As on 28-Aug-2026 13:38EDT

Market cap

$16 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.5

Div. Yield

0 %

Biovie Inc (BIVI) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.11 High: 2.25

52 Week Range

Low: 0.82 High: 3.79

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-11.7
Debt to Equity

0
Book Value

$1361635.2
EPS

$-2.9
Face value

--
Shares outstanding

8,451,148

10 Years Aggregate

CFO

$-75.47 Mln

EBITDA

$-218.20 Mln

Net Profit

$-232.43 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Biovie Inc (BIVI)	86.6	58.0	46.3	33.6	-81.4	-69.3	-51.7
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Biovie Inc (BIVI)	-94.2	-83.9	-83.8	72.7	-74.0	394.9	-0.4
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Biovie Inc (BIVI)	2.2	16.5	0.0	-22.1	--	-0	--	1.5
Arrowhead Pharmaceuticals (ARWR)	84.9	12,304.7	669.5	-320.0	-0.8	-71.1	--	26.4
Ascendis Pharma A/S - ADR	246.7	16,614.0	1,054.4	755.9	5.7	--	19.4	10.1
Cytokinetics Inc (CYTK)	72.3	10,682.6	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.2	13,400.0	2,435.9	860.6	31.0	43	17	7.3
Halozyme Therapeutics (HALO)	105.3	12,277.1	1,663.7	413.6	36.3	430	31.2	83.9
Krystal Biotech (KRYS)	350.5	10,258.4	440.5	241.5	33.4	18.7	42.2	7.3
Madrigal Pharmaceuticals (MDGL)	534.5	11,938.8	1,283.9	-325.1	-19.0	-57.7	--	22.9
Medpace Holdings (MEDP)	603.9	17,326.2	2,782.3	491.5	21.1	110.1	36.5	39.4
Praxis Precision MedicinesÂ Inc (PRAX)	348.4	10,496.2	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Biovie Inc (BIVI)

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment... of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. Read more

President, CEO & Director

Mr. Cuong Viet Do M.B.A.
President, CEO & Director

Mr. Cuong Viet Do M.B.A.
Headquarters

Carson City, NV
Website

https://bioviepharma.com

FAQs for Biovie Inc (BIVI)

What is the current share price of Biovie Inc (BIVI) Today?

The share price of Biovie Inc (BIVI) is $2.17 (NASDAQ) as of 28-Aug-2026 13:38 EDT. Biovie Inc (BIVI) has given a return of -81.41% in the last 3 years.